Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA.
Respir Med. 2020 May;166:105940. doi: 10.1016/j.rmed.2020.105940. Epub 2020 Mar 27.
Bronchiectasis is a complex, chronic respiratory condition, characterized by frequent cough and exertional dyspnea due to a range of conditions that include inherited mucociliary defects, inhalational airway injury, immunodeficiency states and prior respiratory infections. For years, bronchiectasis was classified as either being caused by cystic fibrosis or non-cystic fibrosis. Non-cystic fibrosis bronchiectasis, once considered an orphan disease, is more prevalent worldwide in part due to greater availability of chest computed tomographic imaging. Identification of the cause of non-cystic fibrosis bronchiectasis with the use of chest imaging, laboratory testing, and microbiologic assessment of airway secretions can lead to initiation of specific therapies aimed at slowing disease progression. Nonpharmacologic therapies such as airway clearance techniques and pulmonary rehabilitation improve patient symptoms. Inhaled corticosteroids should not be routinely prescribed unless concomitant asthma or COPD is present. Inhaled antibiotics prescribed to individuals with >3 exacerbations per year are well tolerated, reduce airway bacteria load and may reduce the frequency of exacerbations. Likewise, chronic macrolide therapy reduces the frequency of exacerbations. Medical therapies for cystic fibrosis bronchiectasis may not be effective in treatment of non-cystic fibrosis bronchiectasis.
支气管扩张症是一种复杂的慢性呼吸系统疾病,其特征是频繁咳嗽和运动时呼吸困难,由多种原因引起,包括遗传性黏液纤毛缺陷、吸入性气道损伤、免疫缺陷状态和既往呼吸道感染。多年来,支气管扩张症分为由囊性纤维化或非囊性纤维化引起的两种类型。非囊性纤维化性支气管扩张症曾经被认为是一种罕见病,由于胸部计算机断层成像的广泛应用,在世界范围内更为普遍。通过胸部影像学、实验室检测以及气道分泌物的微生物评估,明确非囊性纤维化性支气管扩张症的病因,可以开始进行旨在减缓疾病进展的特定治疗。非药物治疗,如气道清除技术和肺康复,可以改善患者症状。除非同时存在哮喘或 COPD,否则不应常规开具吸入性皮质类固醇。对于每年有>3 次加重的患者,开具吸入性抗生素的治疗方案耐受性良好,可降低气道细菌负荷,减少加重的频率。同样,慢性大环内酯类药物治疗也可减少加重的频率。囊性纤维化性支气管扩张症的药物治疗方案可能对非囊性纤维化性支气管扩张症的治疗无效。